

ISPOR 41st Health Technology Assessment Roundtable

Real World Evidence and Health Technology Assessment in Asia Pacific

08 September 2018

8:00AM-3:30PM

Grace Room (3rd floor), Keio Plaza Hotel
Tokyo, Japan

Delegates (23)

ISPOR Board of Directors (1)

Federico Augustovski, MD, MSc, PhD, ISPOR President (2018-2019), and Director of Health Economic Evaluations and Technology Assessment, Institute for Clinical Effectiveness and Health Policy, Buenos Aires, Argentina

ISPOR HTA Council (1)

Finn Børllum Kristensen, MD, PhD, Chair, ISPOR Health Technology Assessment Council, Former EUnetHTA Executive Committee Chairman and EUnetHTA Secretariat Director, and Professor, Faculty of Health Sciences, University of Southern Denmark, Copenhagen, Denmark

Australia (1)

Paul Scuffham, PhD, Professor in Health Economics and Director of the Centre for Applied Health Economics, Griffith University, and Deputy Director of the Menzies Health Institute, Queensland, Australia

Bhutan (1)

Deepika Adhikari, Senior Program Officer, Essential Medicines and Technology Division, Department of Medical Services, Ministry of Health, Thimphu, Bhutan

Cambodia (1)

Daravuth Yang, Deputy Director, Department of Drugs and Food, Ministry of Health, Phnom Penh, Cambodia,

China (2)

Kun Zhao, MD, PhD, Professor and Director, Division of Health Technology Assessment, China National Health Development Research Center, National Health Commission, Beijing, China

Xin Sun, PhD, Professor and Director, Chinese Evidence-based Medicine Center, West China Hospital, Sichuan University, Chengdu, China

India (1)

Devarshi Bhattacharyya, MSc, MPH, Assistant Director, Kalam Institute of Health Technology (KIHT), Visakhapatnam, India

Indonesia (1)

Sudigdo Sastroasmoro, MD, PhD, Chair of HTA Committee, Ministry of Health, Jakarta, Indonesia

Japan (5)

Takashi Fukuda, PhD, Director, Department of Health and Welfare Services, National Institute of Public Health, Saitama, Japan

Isao Kamae, MD, DrPH, Professor of Health Technology Assessment and Public Policy, Graduate School of Public Policy, The University of Tokyo, Tokyo, Japan

Shigekazu Komoto, Planning Officer, Medical Economics Division, Health Insurance Bureau, Ministry of Health, Labour and Welfare (MHLW), Tokyo, Japan

Masataka Hasegawa, MD, Deputy Director, Medical Economics Division, Health Insurance Bureau, Ministry of Health, Labour and Welfare (MHLW), Tokyo, Japan

Ruoyan Gai, MSc, PhD, Chief, Division of Policy Evaluation, Department of Health Policy and Chief, Division of Health Technology Assessment, Department of Clinical Epidemiology, National Center for Child Health and Development, Tokyo, Japan

Kazakhstan (2)

Alexander Kostyuk, MD, PhD, Head, Center of Clinical Excellence at Republican Center for HealthCare Development, and Chairman, the HTA Expert Group at Joint Committee for Quality Healthcare Services, Ministry of Health and Social Development, Astana, Kazakhstan

Alima Almadiyeva, MD, MPH, CEO, the Kazakh Agency for Health Technology Assessment (KazAHTA), Astana, Kazakhstan

Malaysia (1)

Ku Nurhasni Ku Abd Rahim, BPharm(USM), MSc HEDM, Senior Principal Assistant Director, Malaysian Health Technology Assessment Section(MaHTAS), Medical Development Division, Ministry of Health, Kuala Lumpur, Malaysia

New Zealand (1)

Richard Milne, PhD, Managing Director, Health Outcomes Associates Ltd, and Associate Professor, School of Population Health, University of Auckland, Auckland, New Zealand

Philippines (1)

Representative (TBD): Philippine Health Insurance Corporation, Pasig City, Philippines

Singapore (1)

Kwong Hoe Ng, Head, Evaluation and Appraisal, Agency for Care Effectiveness, Ministry of Health, Singapore

South Korea (1)

Sukyeong Kim, PhD, Senior Research Fellow, Evidence-based Research Department National Evidence-based Health Care Collaborating Agency (NECA), Seoul, South Korea

Taiwan (1)

Churn-Shiouh Gau, PhD, Chief Executive Director, Center for Drug Evaluation (CDE), Taipei, Taiwan

Thailand (1)

Yot Teerawattananon, PhD, MD, Program Leader, Health Intervention and Technology Assessment Program (HITAP), and General Secretary, National Health Foundation, Nonthaburi, Thailand

ISPOR Staff Members (4)

Nancy S. Berg, CEO/Executive Director, ISPOR, Lawrenceville, NJ, USA

Richard J. Willke, Chief Science Officer, ISPOR, Lawrenceville, NJ, USA

Robert Selby, Director, Global Networks – Asia Pacific, ISPOR, Lawrenceville, NJ, USA

Nancy Chen, Associate Director and Content Strategist, Global Networks – Asia Pacific, ISPOR, Lawrenceville, NJ, USA